



1614
RECEIVED
TECH CENTER 1600/2900 #7
APR 15 2003 JPL
PATENT OFFICE 4/22/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) Levi, et al. Examiner: Unassigned
Serial No.: 10/076,204 Group Art Unit: 1614
Confirmation No: 8595 Docket: 955-16
Filed: February 13, 2002 Dated: April 7, 2003
For: **Method and Compositions
for Reducing Cardiac
Dysfunctions with a
Selective Histamine H₃
Receptor Agonist**

Commissioner for Patents
Washington, DC 20231

*I hereby certify this correspondence is being deposited
with the United States Postal Service as first class mail,
postpaid in an envelope, addressed to:
Commissioner for Patents, Washington, D.C.*

20231 on April 7, 2003

Dated: 4/7/03

Julie L. Watts

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In order to fulfill the requirements of candor and good faith set forth in 37 C.F.R. §1.56, Applicants submit herewith the following Information Disclosure Statement in accordance with the provisions of 37 C.F.R. §1.97 and §1.98.

NON-PATENT PUBLICATIONS

1. Akagi, et al., "Role of histamine H₃ receptor on hypoxia-reoxygenation-induced cardiac dysfunction in guinea pigs", PubMed No. 8750792, *Methods Find Exp. Clin. Pharmacol.*, 1995, Vol. 17 Suppl C:30-35. (abstract only).
2. Imamura, Michiaki, et al., "Histamine H₃-Receptor-Mediated Inhibition of Calcitonin Gene-Related Peptide Release From Cardiac C Fibers", *Circulation Research* 1996, 78(5):863-869.
3. Luo, Xiao-Xing, et al., "Histamine H₃-receptors inhibit sympathetic neurotransmission in guinea pig myocardium", *European Journal of Pharmacology* 1991, 204:311-314.


Application No.: 10/076,204
Filing Date: February 13, 2002
Docket No.: 955-16
Page 2 of 2

The above-referenced documents are listed on PTO Form 1449. We have enclosed the cited documents to facilitate reference to them. The Examiner is respectfully requested to consider these publications in their entirety, and to indicate that he or she has done so by initializing the enclosed form PTO 1449.

The Supplemental Information Disclosure Statement is being submitted before issuance of the first Office Action. Therefore, it is believed that no fee is due, however, if a fee is due, the commissioner is hereby authorized to charge Deposit Account No. 08-2461 for any additional fees associated with this communication. A duplicate copy of this sheet is attached.

Applicants are not aware of any other references to be identified at this time. If the Examiner has any questions or comments relating to the present application, he or she is respectfully invited to contact Applicants' agent at the telephone number set forth below.

Respectfully submitted,


Edna I. Gergel, Ph.D.
Registration No.: 50,819
Agent for Applicant(s)

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(516) 822-3550
EIG:jlw

171028_1